Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Life Technologies Corporation
CARLSBAD, Calif., Jan. 9, 2014 /PRNewswire/ -- Life Technologies (NASDAQ: LIFE) has completed a multi-year license and supply agreement with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, that gives Quest rights to develop molecular tests on the Ion Torrent™ next-generation sequencing platform. Under the agreement, Quest may use the platform and related consumables to independently develop new tests for numerous areas of their business.
DNA sequencing is a process that determines the order of individual nucleotides of DNA molecules across a single gene, several genes or a full genome. Unlike older technologies, next-generation sequencing (NGS) platforms can sequence multiple molecules simultaneously, providing greater information about the genetic basis of disease for lower cost. Ion Torrent™ technology combines speed and reliability with the ability to analyze large, multi-gene DNA or RNA panels from extremely small samples, such as those obtained from needle aspirates, circulating nucleic acids and circulating tumor cells.
"Next-generation sequencing is a highly advanced technology with great potential to improve clinical care, research and cost savings across several fields of medicine," said Jay Wohlgemuth, M.D., Senior Vice President, Science and Innovation, Quest Diagnostics. "Quest is actively developing NGS-based tests and working with top providers, such as Life Technologies, to expand our capabilities in this exciting new field. With this agreement, we can build on our successes in NGS to accelerate the future clinical benefit and positive impact of this technology for patients and providers across several disease areas, including cancer, neurology and women's health."
This new agreement extends the range of applications in which Quest may develop tests on the Ion Torrent technology to more than a dozen.
"The power of next-generation sequencing technology is transforming healthcare by giving physicians an opportunity to understand disease at the molecular level," said Ronnie Andrews, president, Genetic Analysis and Medical Science at Life Technologies. "Quest Diagnostics is a pioneer at bringing new technologies into the clinic through their centers of excellence and is the ideal partner to leverage the potential of Ion Torrent™ technology to improve human health."
The regulatory status of Ion Torrent products can be found on the Life Technologies website.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions are secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact:
©2012 PR Newswire. All Rights Reserved.
All content © Copyright 2000 - 2014 WorldNow and KIII. All Rights Reserved.